DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

BMO Capital Upgrades Blueprint Medicines to Outperform, Raises Price Target to $89

BMO Capital analyst George Farmer upgrades Blueprint Medicines (NASDAQ:BPMC) from Market Perform to Outperform and raises the price target from $74 to $89.

Benzinga · 03/17/2020 10:18

BMO Capital analyst George Farmer upgrades Blueprint Medicines (NASDAQ:BPMC) from Market Perform to Outperform and raises the price target from $74 to $89.